z-logo
Premium
Retrospective analysis of factors influencing oncologic outcome in 590 patients with early‐intermediate glottic cancer treated by transoral laser microsurgery
Author(s) -
Ansarin Mohssen,
Cattaneo Augusto,
De Benedetto Luigi,
Zorzi Stefano,
Lombardi Francesca,
Alterio Daniela,
Rocca Maria Cossu,
Scelsi Daniele,
Preda Lorenzo,
Chiesa Fausto,
Santoro Luigi
Publication year - 2017
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24534
Subject(s) - transoral laser microsurgery , medicine , cordectomy , larynx , tracheotomy , microsurgery , surgery , retrospective cohort study , occult , head and neck cancer , radiation therapy , cancer , laryngectomy , pathology , alternative medicine
Background The purpose of this study was to identify the factors influencing oncologic outcomes for patients with early‐intermediate glottic cancer treated by transoral laser microsurgery (TLM). Methods This was a retrospective mono‐institutional study. A total of 590 patients with cTis‐cT3 glottic cancer underwent TLM with curative intent. Results TLM alone was performed in 538 patients (91.2%) and TLM followed by adjuvant radiotherapy (RT) was done in 52 (8.8%). Five‐year recurrence‐free survival (RFS) and 10‐year overall survival (OS) were 85.3% and 74.7%, respectively. The larynx‐preservation ratio was 95.9%. In particular, from our data, we found that occult metastases were rare (1.2%); preventive tracheotomy was not necessary; the local recurrence rate of Tis was similar to that in the T2 and T3 group; and no major or lethal complications were observed. Conclusion Age (>60 vs ≤60), type of cordectomy (≥IV vs ≤III), status of margins, fixed arytenoid, and pathologic T classification, were the variables associated with RFS, OS, and organ‐preservation rate. © 2016 Wiley Periodicals, Head Neck 39: 71–81, 2017

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here